Physician profile
Megan S Brown
NPI 1851956874
$3,430.62
in general payments reported to CMS, 2019-2025
36 companies · $1,054 in 2025
The $1,054 reported for 2025 was more than what 86% of Nurse Practitioner providers received nationally (typical 2025 total: $174).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $56.04 · 2023: $759 · 2024: $1,562 · 2025: $1,054.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,655 · Education: $719.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,655.29 |
| Education | $719.29 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $364.93 | 2023-2025 | |
| Merck Sharp & Dohme LLC | $285.42 | 2023-2025 | Keytruda, Welireg, Keytruda Qlex |
| Incyte Corporation | $241.79 | 2022-2025 | Monjuvi, Jakafi, Pemazyre |
| Janssen Biotech, INC. | $205.68 | 2023-2025 | Rybrevant, Tecvayli, Darzalex |
| Stemline Therapeutics INC. | $203.49 | 2023-2025 | Orserdu |
| Genentech USA, INC. | $194.02 | 2022-2025 | Polivy, Tecentriq, Venclexta |
| Aveo Pharmaceuticals, INC. | $168.31 | 2024-2025 | |
| Novartis Pharmaceuticals Corporation | $155.80 | 2023-2025 | |
| Daiichi Sankyo INC. | $129.58 | 2023-2024 | Enhertu |
| Astrazeneca Pharmaceuticals LP | $128.77 | 2023-2025 | Tagrisso, Enhertu, Lynparza |
| Abbvie INC. | $119.59 | 2023-2025 | |
| Takeda Pharmaceuticals U.S.A., INC. | $110.92 | 2022-2025 | Iclusig, Alunbrig, Fruzaqla |
| Array Biopharma INC | $102.05 | 2023-2025 | Mektovi, Braftovi, Xalkori |
| Seagen INC. | $99.99 | 2024 | |
| Sobi, INC | $83.99 | 2025 |
Show all 36 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $79.45 | 2023-2024 | Ojjaara, Zejula, Jemperli |
| Gilead Sciences, INC. | $75.64 | 2023-2024 | Trodelvy |
| Legend Biotech USA INC. | $71.67 | 2024 | |
| Eisai INC. | $69.68 | 2023-2024 | |
| Tempus Ai, INC | $65.83 | 2024-2025 | Xt Cdx |
| Astellas Pharma US INC | $63.33 | 2023-2024 | Padcev, Vyloy |
| Regeneron Healthcare Solutions, INC. | $60.58 | 2023-2025 | Libtayo |
| Amgen INC. | $58.30 | 2023-2024 | Lumakras, Uplizna, Evenity |
| Lilly USA, LLC | $51.91 | 2024-2025 | Jaypirca, Verzenio, Retevmo |
| Pharmaessentia USA Corporation | $39.61 | 2023-2024 | Besremi |
| Alexion Pharmaceuticals, INC. | $28.00 | 2024 | Ultomiris |
| Janssen Pharmaceuticals, INC | $22.00 | 2025 | Rybrevant |
| Servier Pharmaceuticals LLC | $20.66 | 2025 | |
| Genmab U.S., INC. | $18.93 | 2023 | Tivdak |
| Mirati Therapeutics, INC. | $17.58 | 2024 | Krazati |
| Sumitomo Pharma America, INC. | $16.83 | 2023 | Orgovyx |
| Genzyme Corporation | $16.22 | 2025 | |
| E.R. Squibb & Sons, L.L.C. | $15.98 | 2024 | Krazati |
| Bayer Healthcare Pharmaceuticals INC. | $15.62 | 2023 | |
| Celgene Corporation | $14.33 | 2023 | Reblozyl |
| Geron Corporation | $14.14 | 2025 | Rytelo |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Megan Brown listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.